Functional characterisation in vitro of an Affibody® molecule aimed for vascular targeted tumour therapy
Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
In a certain type of cancer immunotherapy, IL-2 is administered in high doses to the patient inorder to trigger an immune response against tumour cells. The high dose administered leads tohigh general toxicity. By targeting IL-2 to the sites of the tumours, the dose can be decreasedand toxicity reduced. Here, a PDGFR-! specific fusion protein (Z03358-ABD-IL2) aimed fordelivery of IL-2 to tumour vasculature, has been characterised in vitro for IL-2-activity andtarget binding. Also, two PDGFR-! specific Affibody molecules (Z02465 and Z02483) havebeen characterised in vitro for target binding and biological blocking activity. Results showedthat Z03358-ABD-IL2 had full IL-2 activity, but decreased target binding. In contrast, fulltarget binding and blocking capacity was confirmed with Z02465 and Z02483. From thiswork it can be concluded that Z03358-ABD-IL2 has activity in all parts, but re-cloning withZ02465 or Z02483 should be considered for full target binding capacity.
Place, publisher, year, edition, pages
2011. , 36 p.
Cancer, tumour vasculature, tumour targeting, IL-2, Affibody molecule, pericyte, PDGFR-beta
IdentifiersURN: urn:nbn:se:uu:diva-155883OAI: oai:DiVA.org:uu-155883DiVA: diva2:429023
Molecular Biotechnology Engineering Programme
UppsokPhysics, Chemistry, Mathematics
Frejd, FredrikHöidén-Guthenberg, Ingmarie
Lars-Göran Josefsson, Lars-Göran